Rob Dale
Rob runs technical and SEO strategy at Business of Cannabis and has a Master’s in Clinical Exercise Physiology. He blends search know-how with a solid grasp of clinical methods to spot what actually matters in new studies and regulations. Day to day, he helps shape evidence-based explainers and features, translating data into clear, useful insights for industry pros.
Rob Dale · page 3
- Markets & Stocks
Cannabis Stocks Today — Tuesday 19 May 2026: Trulieve Trades at $8.02 as US Operators Recover While Canopy Slips to $0.98
Pre-market on Tuesday 19 May, cannabis stocks carry Monday’s close as their reference point, with the US session due to open at 13:30 UTC.
- Cannabis Daily News
Cannabis News Today — Tuesday 19 May 2026: FDA Backs Cannabis Pain Drug as Post-Rescheduling Wave Reaches States and Markets
The downstream effects of April’s federal rescheduling continued to accelerate on Monday.
- Markets & Stocks
Cannabis Stocks Today — Monday 18 May 2026: Curaleaf Sits at $3.41 as US Operators Register Heavy Friday Losses
The US cannabis sector approaches this week’s open carrying the weight of a difficult Friday session.
- Cannabis Daily News
Cannabis News Today — Monday 18 May 2026: RICO Class Action Names Three US Operators as Canada Leads Germany’s Medical Cannabis Imports
A 320-page RICO complaint against three of America’s largest cannabis operators landed in insurance and legal analysis this morning, signalling the litigation risks that federal rescheduling may accelerate.
- Cannabis Daily News
Cannabis News Today — Friday 15 May 2026: Congress Fractures on Rescheduling as Delaware Court Extends Bankruptcy Protection to Cannabis
Congress pulled in opposite directions on cannabis on Thursday: the House Appropriations Committee voted to bar further federal rescheduling, even as the full chamber passed a bipartisan amendment giving veterans the right to discuss medical cannabis with their VA doctors.
- Markets & Stocks
Cannabis Stocks Today — Thursday 14 May 2026: GrowGeneration Trades at $1.61 as AFC Gamma Slides 9%
Thursday’s pre-market window, with US equities not opening until 14:30 BST, finds cannabis stocks at Wednesday’s close — a session that left the sector modestly tilted to the downside, with 19 tickers lower, 15 higher, and four unchanged.
- Cannabis Daily News
Cannabis News Today — Thursday 14 May 2026: Congress targets unregulated cannabinoids as operators race for Schedule III registration
Two threads dominated the past 24 hours in cannabis policy. The House Appropriations Committee moved to increase federal scrutiny of unregulated cannabinoid products, while state-licensed operators competed to file DEA applications under the 60-day Schedule III registration window.
- Markets & Stocks
Cannabis Stocks Today — Wednesday 13 May 2026: Organigram Slides to $1.11 as Sector Posts Broad Losses
Cannabis stocks carry the losses from Tuesday’s session into Wednesday morning, with US markets yet to open and all prices reflecting the 12 May close.
- Markets & Stocks
Cannabis Stocks Today — Tuesday 12 May 2026: Cronos Trades at $2.75 as Ayr Wellness Slips Toward $0.01
Cannabis equities head into Tuesday’s pre-market session with the sector broadly divided, following a Monday close in which upward and downward pressure across the tracked universe roughly offset one another.
- Cannabis Daily News
Cannabis News Today — Tuesday 12 May 2026: Federal rescheduling machinery shifts into gear as Cronos posts record quarter and Massachusetts repels rollback
Three and a half weeks after the Justice Department moved state-licensed medical cannabis to Schedule III, a cluster of practical consequences is landing simultaneously.
- M&A Activity
Cannabis Telehealth Platform Veri Medtech Sets Terms for $15m Nasdaq IPO
Veriheal parent Veri Medtech Holdings has priced a $15m IPO at $4 per share, with plans to uplist from the OTC market to Nasdaq.
- Cannabis Daily News
Cannabis News Today — Friday 8 May 2026: Repeal Efforts Collapse as Industry Faces Fresh Legal and Strategic Tests
Repeal campaigns stall in Arizona as Idaho medical cannabis activists oversubscribe their ballot push, fresh research on legalisation arrests lands, and the industry’s medical-marketing claims and Tilray’s expansion playbook draw scrutiny.
